Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 1371 Lung cancer is the leading cause of cancer-related death in the United States. Most lung cancer cells are resistant to chemotherapy, the mechanism of which is not well understood. Combinations of multiple anti-cancer drugs may be an effective strategy to improve the efficacy of lung cancer therapy. In this study, we examined the anti-cancer activity of tumor necrosis factor (TNF) combined with the flavonoid luteolin and found that luteolin treatment significantly sensitized lung cancer cells to TNF-induced cell death. The cell death induced by TNF and luteolin treatment is mainly apoptosis, which was detected both morphologically and biochemically. Although luteolin treatment had no effect on the expression levels of the key components of TNF receptor I signaling cascade including TRADD, RIP, TRAF2 and FADD, the TNF-induced NF-κB activation was effectively blocked, which is evidenced by NF-κB reporter assays and Western blots for the expression of NF-κB targeted anti-apoptosis genes. In the NF-κB-disabled cells expressing a non-degradable IκBα mutant (IκBαAA), the synergistic cytotoxicity induced by Luteolin and TNF treatment was abolished, suggesting that the potentiation of TNF-induced cell death by luteolin is achieved by blocking TNF-induced NF-κB activation. The target of the NF-κB pathway by luteolin appears to be downstream of IκB, since treatment with luteolin did not affect the TNF-induced IκBα phosphorylation and degradation. Altered modification of the RelA/p65 subunit of NF-κB in luteolin treated cells was detected, suggesting that modulation of the transcription activity contributes to the blockage of NF-κB by luteolin. In addition, we also found that luteolin augmented the TNF-induced c-Jun N-terminal protein kinase (JNK) activation, and suppression of JNK activity with a specific chemical inhibitor significantly inhibited the synergistic cytotoxicity induced by luteolin and TNF treatment. Thus activation of JNK may also contribute to the potentiation of cell death by luteolin. Taken together, our results suggest that luteolin potentiates TNF-induced lung cancer cell death through blockage of NF-κB and activation of JNK, and the combined treatment with luteolin and TNF could be useful for treating lung cancer.

Luteolin Enhances Tnf-Related Apoptosis-Inducing Ligand'S Anticancer Activity in A Lung Cancer Xenograft Mouse Model

Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission

Effect of Luteolin and its combination with chemotherapeutic drugs on cytotoxicity of cancer cells]

Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization.

Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.

Sensitization of Tumor Necrosis Factor-Induced Lung Cancer Cell Eath by Luteolin

Luteolin Sensitizes Two Oxaliplatin-Resistant Colorectal Cancer Cell Lines to Chemotherapeutic Drugs Via Inhibition of the Nrf2 Pathway

Research progress on anti-tumor effects of luteolin]

Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non‐small cell lung cancer

Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis

Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells

A Critical Role Of Luteolin-Induced Reactive Oxygen Species In Blockage Of Tumor Necrosis Factor-Activated Nuclear Factor-Kappa B Pathway And Sensitization Of Apoptosis In Lung Cancer Cells

Luteolin Synergistically Enhances Antitumor Activity of Oxaliplatin in Colorectal Carcinoma via AMPK Inhibition

Luteolin Potentiates Low-Dose Oxaliplatin-Induced Inhibitory Effects on Cell Proliferation in Gastric Cancer by Inducing G2/M Cell Cycle Arrest and Apoptosis.

Luteolin is Effective in the Non‐small Cell Lung Cancer Model with L858R/T790M EGF Receptor Mutation and Erlotinib Resistance

Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (trail) Apoptosis in Vitro but Not in Vivo

Luteolin suppresses growth and migration of human lung cancer cells

Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway.

Anti-proliferation Activity of Luteolin and Its Role in Combined Chemotherapy on Lung Cancer A549 Cells

A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.